Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | CA4 | P22748 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115255 | 0.87 | CA1 (0.61) | CA9CA1CA2CA4KMT2A | |
| SCHEMBL3493204 | 0.83 | ADORA2A (0.40) | CA9CA1CA2CA4KMT2A | |
| SCHEMBL3114826 | 0.75 | ROCK1 (0.40) | KMT2AMEN1ALDH1A1HTTHPGD | |
| SCHEMBL3109595 | 0.74 | PTGER4 (0.39) | CA2ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL3109603 | 0.74 | PTGER4 (0.39) | CA2ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL3116023 | 0.74 | CA1 (0.52) | CA9CA1CA2CA4KMT2A | |
| SCHEMBL5250501 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1HTTHPGDLMNA | |
| SCHEMBL3107424 | 0.72 | KDM4E (0.57) | CA9CA1CA2CA4KMT2A | |
| SCHEMBL5245240 | 0.72 | HPGD (0.45) | KMT2AMEN1HTTHPGDPOLB | |
| SCHEMBL5246308 | 0.71 | RAB9A (0.42) | KDM4EALDH1A1HTTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CA9 572/4885CA1 2606/4885CA2 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.